Designing Smaller CCK Peptides That Trigger Satiety for Obesity Treatment | Research

The takeaway

New hybrid CCK-A receptor agonist peptides combining features of hexa- and tetrapeptide classes showed potent satiety-inducing activity, advancing the design of peptide-based obesity treatments.

Potent + selective
Hybrid CCK peptides achieved strong CCK-A binding (satiety) with selectivity over CCK-B (avoids unwanted anxiety effects)

What the researchers found

Hybrid CCK-A agonist peptides combining structural features of hexapeptide and tetrapeptide classes showed potent receptor binding and selectivity, advancing design of satiety-inducing peptide drugs for obesity.

Why it matters

Obesity is a global health crisis. CCK-based drugs that trigger natural satiety could help people eat less without the side effects of stimulant-based appetite suppressants.

How the study worked

In-vitro study designing and testing new CCK peptide analogs for CCK-A receptor binding affinity, selectivity over CCK-B, and functional activity.

What this study cannot tell us

In-vitro binding and selectivity data only. In-vivo satiety effects not demonstrated for the new hybrids. Peptide stability and oral bioavailability are ongoing challenges.

How to read the evidence

Preliminary in-vitro evidence with clear receptor pharmacology but no in-vivo efficacy data.

When this study was published

Published in 2000. CCK-based obesity approaches have been explored further, though GLP-1 agonists have dominated the obesity drug landscape.

The bigger picture

The body has built-in satiety signals. Rather than suppressing appetite artificially, drugs that enhance natural satiety peptide signaling could provide safer, more effective obesity treatment.

Questions still open

Can these hybrids be made orally bioavailable?
Do they produce sustained satiety in animal feeding studies?
How do they compare to GLP-1-based obesity drugs?

Common questions

What is CCK?

Cholecystokinin is a gut hormone released after eating that tells your brain you're full. Drugs that mimic CCK could help people feel satisfied sooner and eat less — a natural approach to weight management.

How does this compare to drugs like Ozempic?

Ozempic works through the GLP-1 system, a different satiety pathway. CCK-based drugs would target another satiety signal. In theory, combining both could produce even stronger satiety effects.

Read the original research

CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.

Journal of medicinal chemistry, 43(12), 2350-5

View on PubMed ↗

Citation

Pierson, M E; Comstock, J M; Simmons, R D; Julien, R; Kaiser, F; Rosamond, J D. (2000). CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.. Journal of medicinal chemistry, 43(12), 2350-5.